dwb2023/gtopdb-target-family-interaction-detail huggingface dataset:
Target family: Type XIII RTKs: Ephrin receptor family (type: catalytic_receptor)
Target: EPH receptor B1

Ligand: compound 20 [PMID: 23489211] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.420000076293945 pIC50
Reference (Journal): Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor.
Published in: J Med Chem

Ligand: compound 66 [PMID: 19788238] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 8.960000038146973 pIC50
Reference (Journal): Structure-based optimization of potent and selective inhibitors of the tyrosine kinase erythropoietin producing human hepatocellular carcinoma receptor B4 (EphB4).
Published in: J Med Chem
Target family: Type XIII RTKs: Ephrin receptor family (type: catalytic_receptor)
Target: EPH receptor B2

Ligand: compound 20 [PMID: 23489211] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.420000076293945 pIC50
Reference (Journal): Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor.
Published in: J Med Chem

Ligand: compound 66 [PMID: 19788238] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.920000076293945 pIC50
Reference (Journal): Structure-based optimization of potent and selective inhibitors of the tyrosine kinase erythropoietin producing human hepatocellular carcinoma receptor B4 (EphB4).
Published in: J Med Chem
Target family: Type XIII RTKs: Ephrin receptor family (type: catalytic_receptor)
Target: EPH receptor A7

Ligand: compound 20 [PMID: 23489211] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.679999828338623 pIC50
Reference (Journal): Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor.
Published in: J Med Chem
Target family: Type XIII RTKs: Ephrin receptor family (type: catalytic_receptor)
Target: EPH receptor B2

Ligand: RIPK3 inhibitor 18 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8 pIC50
Reference (Journal): Identification of RIPK3 Type II Inhibitors Using High-Throughput Mechanistic Studies in Hit Triage
Published in: ACS Med Chem Lett
Target family: Type XIII RTKs: Ephrin receptor family (type: catalytic_receptor)
Target: EPH receptor B3

Ligand: compound 20 [PMID: 23489211] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.360000133514404 pIC50
Reference (Journal): Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor.
Published in: J Med Chem

Ligand: compound 66 [PMID: 19788238] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.820000171661377 pIC50
Reference (Journal): Structure-based optimization of potent and selective inhibitors of the tyrosine kinase erythropoietin producing human hepatocellular carcinoma receptor B4 (EphB4).
Published in: J Med Chem
Target family: Type XIII RTKs: Ephrin receptor family (type: catalytic_receptor)
Target: EPH receptor B4

Ligand: compound 20 [PMID: 23489211] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.360000133514404 pIC50
Reference (Journal): Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor.
Published in: J Med Chem

Ligand: compound 66 [PMID: 19788238] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.800000190734863 pIC50
Reference (Journal): Structure-based optimization of potent and selective inhibitors of the tyrosine kinase erythropoietin producing human hepatocellular carcinoma receptor B4 (EphB4).
Published in: J Med Chem

Ligand: tesevatinib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 8.850000381469727 pIC50
Reference (Journal): Inhibition of the T790M gatekeeper mutant of the epidermal growth factor receptor by EXEL-7647.
Published in: Clin Cancer Res
Target family: Type XIII RTKs: Ephrin receptor family (type: catalytic_receptor)
Target: EPH receptor B6

Ligand: compound 20 [PMID: 23489211] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.239999771118164 pIC50
Reference (Journal): Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor.
Published in: J Med Chem
Target family: Type XIII RTKs: Ephrin receptor family (type: catalytic_receptor)
Target: EPH receptor A2

Ligand: compound 20 [PMID: 23489211] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.659999847412109 pIC50
Reference (Journal): Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor.
Published in: J Med Chem
Target family: Type XIII RTKs: Ephrin receptor family (type: catalytic_receptor)
Target: EPH receptor A1

Ligand: compound 66 [PMID: 19788238] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.539999961853027 pIC50
Reference (Journal): Structure-based optimization of potent and selective inhibitors of the tyrosine kinase erythropoietin producing human hepatocellular carcinoma receptor B4 (EphB4).
Published in: J Med Chem

Ligand: compound 20 [PMID: 23489211] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 5.639999866485596 pIC50
Reference (Journal): Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor.
Published in: J Med Chem
Target family: Type XIII RTKs: Ephrin receptor family (type: catalytic_receptor)
Target: EPH receptor A4

Ligand: compound 20 [PMID: 23489211] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.570000171661377 pIC50
Reference (Journal): Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor.
Published in: J Med Chem

Ligand: compound 66 [PMID: 19788238] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.479999542236328 pIC50
Reference (Journal): Structure-based optimization of potent and selective inhibitors of the tyrosine kinase erythropoietin producing human hepatocellular carcinoma receptor B4 (EphB4).
Published in: J Med Chem
Target family: Type XIII RTKs: Ephrin receptor family (type: catalytic_receptor)
Target: EPH receptor A5

Ligand: compound 20 [PMID: 23489211] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.619999885559082 pIC50
Reference (Journal): Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor.
Published in: J Med Chem

Ligand: compound 66 [PMID: 19788238] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.520000457763672 pIC50
Reference (Journal): Structure-based optimization of potent and selective inhibitors of the tyrosine kinase erythropoietin producing human hepatocellular carcinoma receptor B4 (EphB4).
Published in: J Med Chem

Ligand: RIPK3 inhibitor 18 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.849999904632568 pIC50
Reference (Journal): Identification of RIPK3 Type II Inhibitors Using High-Throughput Mechanistic Studies in Hit Triage
Published in: ACS Med Chem Lett
Target family: Type XIII RTKs: Ephrin receptor family (type: catalytic_receptor)
Target: EPH receptor A6

Ligand: compound 20 [PMID: 23489211] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.820000171661377 pIC50
Reference (Journal): Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor.
Published in: J Med Chem
Target family: Type XIII RTKs: Ephrin receptor family (type: catalytic_receptor)
Target: EPH receptor A3

Ligand: sitravatinib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 9 pIC50
Reference (Journal): Significant blockade of multiple receptor tyrosine kinases by MGCD516 (Sitravatinib), a novel small molecule inhibitor, shows potent anti-tumor activity in preclinical models of sarcoma.
Published in: Oncotarget

Ligand: fibatuzumab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: no
Primary target: yes
Median affinity: 9 pKd
Reference (Patent): Antibodies to EphA3.

Ligand: fibatuzumab (Antibody)
Interaction type: Antibody
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 9 pKd
Reference (Patent): Antibodies to EphA3.

Ligand: compound 8h [PMID: 21561767] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.920000076293945 pIC50
Reference (Journal): Discovery of 5-(arenethynyl) hetero-monocyclic derivatives as potent inhibitors of BCR-ABL including the T315I gatekeeper mutant.
Published in: Bioorg Med Chem Lett

Ligand: compound 66 [PMID: 19788238] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.400000095367432 pIC50
Reference (Journal): Structure-based optimization of potent and selective inhibitors of the tyrosine kinase erythropoietin producing human hepatocellular carcinoma receptor B4 (EphB4).
Published in: J Med Chem

Ligand: compound 20 [PMID: 23489211] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.599999904632568 pIC50
Reference (Journal): Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor.
Published in: J Med Chem
Target family: Type XIII RTKs: Ephrin receptor family (type: catalytic_receptor)
Target: EPH receptor A2

Ligand: dorsomorphin (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.960000038146973 pIC50
Reference (Journal): The rational design of a novel potent analogue of the 5'-AMP-activated protein kinase inhibitor compound C with improved selectivity and cellular activity.
Published in: Bioorg Med Chem Lett

Ligand: DDR1/2 inhibitor 5n (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.590000152587891 pKd
Reference (Journal): Design, Synthesis, and Biological Evaluation of 3-(Imidazo[1,2- a]pyrazin-3-ylethynyl)-4-isopropyl- N-(3-((4-methylpiperazin-1-yl)methyl)-5-(trifluoromethyl)phenyl)benzamide as a Dual Inhibitor of Discoidin Domain Receptors 1 and 2.
Published in: J Med Chem

Ligand: compound 8h [PMID: 21561767] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 9.220000267028809 pIC50
Reference (Journal): Discovery of 5-(arenethynyl) hetero-monocyclic derivatives as potent inhibitors of BCR-ABL including the T315I gatekeeper mutant.
Published in: Bioorg Med Chem Lett

Ligand: compound 66 [PMID: 19788238] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.640000343322754 pIC50
Reference (Journal): Structure-based optimization of potent and selective inhibitors of the tyrosine kinase erythropoietin producing human hepatocellular carcinoma receptor B4 (EphB4).
Published in: J Med Chem
Target family: Type XII RTKs: TIE family of angiopoietin receptors (type: catalytic_receptor)
Target: tyrosine kinase with immunoglobulin like and EGF like domains 1

Ligand: BIIB091 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.400000095367432 pKd
Reference (Journal): Discovery and Preclinical Characterization of BIIB091, a Reversible, Selective BTK Inhibitor for the Treatment of Multiple Sclerosis.
Published in: J Med Chem

Ligand: merestinib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 9.050000190734863 pKd
Reference (Journal): LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models.
Published in: Invest New Drugs

Ligand: compound R-16 [PMID: 21967808] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Improvement in oral bioavailability of 2,4-diaminopyrimidine c-Met inhibitors by incorporation of a 3-amidobenzazepin-2-one group.
Published in: Bioorg Med Chem

Ligand: compound 6li [Chan et al., 2022] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 9.130000114440918 pKd
Reference (Journal): Discovery of 3-Aminopyrazole Derivatives as New Potent and Orally Bioavailable AXL Inhibitors
Published in: Journal of Nedicinal Chemistry
Target family: Type XI RTKs: TAM (TYRO3-, AXL- and MER-TK) receptor family (type: catalytic_receptor)
Target: AXL receptor tyrosine kinase

Ligand: RIPK1 inhibitor 22b (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.460000038146973 pIC50
Reference (Journal): Identification of 5-(2,3-Dihydro-1 H-indol-5-yl)-7 H-pyrrolo[2,3- d]pyrimidin-4-amine Derivatives as a New Class of Receptor-Interacting Protein Kinase 1 (RIPK1) Inhibitors, Which Showed Potent Activity in a Tumor Metastasis Model.
Published in: J Med Chem
Target family: Type XI RTKs: TAM (TYRO3-, AXL- and MER-TK) receptor family (type: catalytic_receptor)
Target: AXL receptor tyrosine kinase

Ligand: zanzalintinib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8 pIC50
Reference (Patent): Compounds for the treatment of kinase-dependent disorders

Ligand: UNC8969 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.279999732971191 pIC50
Reference (Journal): Discovery of Novel Macrocyclic MERTK/AXL Dual Inhibitors.
Published in: J Med Chem

Ligand: UNC4203 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.400000095367432 pKi
Reference (Journal): Highly Selective MERTK Inhibitors Achieved by a Single Methyl Group.
Published in: J Med Chem

Ligand: SLC-391 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity:  pIC50
Reference (Patent): Aminopyridine derivatives as tam family kinase inhibitors
Target family: Type XI RTKs: TAM (TYRO3-, AXL- and MER-TK) receptor family (type: catalytic_receptor)
Target: TYRO3 protein tyrosine kinase

Ligand: UNC8969 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.179999828338623 pIC50
Reference (Journal): Discovery of Novel Macrocyclic MERTK/AXL Dual Inhibitors.
Published in: J Med Chem

Ligand: UNC4203 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.40999984741211 pKi
Reference (Journal): Highly Selective MERTK Inhibitors Achieved by a Single Methyl Group.
Published in: J Med Chem

Ligand: SLC-391 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.300000190734863 pIC50
Reference (Patent): Aminopyridine derivatives as tam family kinase inhibitors

Ligand: protein S (Peptide)
Interaction type: None
Action: None
Ligand approved: no
Median affinity:  -
Reference (Journal): The anticoagulation factor protein S and its relative, Gas6, are ligands for the Tyro 3/Axl family of receptor tyrosine kinases.
Published in: Cell

Ligand: LDC1267 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.100000381469727 pIC50
Reference (Journal): The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells.
Published in: Nature

Ligand: growth arrest specific protein 6 (Peptide)
Interaction type: None
Action: None
Ligand approved: no
Median affinity:  -
Reference (Journal): Identification of the product of growth arrest-specific gene 6 as a common ligand for Axl, Sky, and Mer receptor tyrosine kinases.
Published in: J Biol Chem

Ligand: compound 21 [PMID: 23312943] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 9.149999618530273 pIC50
Reference (Journal): Optimization of highly selective 2,4-diaminopyrimidine-5-carboxamide inhibitors of Sky kinase.
Published in: Bioorg Med Chem Lett

Ligand: BMS-777607 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.369999885559082 pIC50
Reference (Journal): Discovery of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a selective and orally efficacious inhibitor of the Met kinase superfamily.
Published in: J Med Chem
Target family: Type XI RTKs: TAM (TYRO3-, AXL- and MER-TK) receptor family (type: catalytic_receptor)
Target: MER proto-oncogene, tyrosine kinase

Ligand: zanzalintinib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8 pIC50
Reference (Patent): Compounds for the treatment of kinase-dependent disorders

Ligand: UNC8969 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.960000038146973 pIC50
Reference (Journal): Discovery of Novel Macrocyclic MERTK/AXL Dual Inhibitors.
Published in: J Med Chem

Ligand: UNC4203 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 9.369999885559082 pKi
Reference (Journal): Highly Selective MERTK Inhibitors Achieved by a Single Methyl Group.
Published in: J Med Chem

Ligand: SLC-391 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.300000190734863 pIC50
Reference (Patent): Aminopyridine derivatives as tam family kinase inhibitors

Ligand: sitravatinib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.699999809265137 pIC50
Reference (Journal): Significant blockade of multiple receptor tyrosine kinases by MGCD516 (Sitravatinib), a novel small molecule inhibitor, shows potent anti-tumor activity in preclinical models of sarcoma.
Published in: Oncotarget

Ligand: RIPK1 inhibitor 22b (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.539999961853027 pIC50
Reference (Journal): Identification of 5-(2,3-Dihydro-1 H-indol-5-yl)-7 H-pyrrolo[2,3- d]pyrimidin-4-amine Derivatives as a New Class of Receptor-Interacting Protein Kinase 1 (RIPK1) Inhibitors, Which Showed Potent Activity in a Tumor Metastasis Model.
Published in: J Med Chem

Ligand: RIPK1 inhibitor 22b (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.539999961853027 pIC50
Reference (Journal): Identification of 5-(2,3-Dihydro-1 H-indol-5-yl)-7 H-pyrrolo[2,3- d]pyrimidin-4-amine Derivatives as a New Class of Receptor-Interacting Protein Kinase 1 (RIPK1) Inhibitors, Which Showed Potent Activity in a Tumor Metastasis Model.
Published in: J Med Chem

Ligand: MK-2461 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.619999885559082 pIC50
Reference (Journal): MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor.
Published in: Cancer Res
Target family: Type XIX RTKs: Leukocyte tyrosine kinase (LTK) receptor family (type: catalytic_receptor)
Target: leukocyte receptor tyrosine kinase

Ligand: gilteritinib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (2018), EMA (2019)
Primary target: no
Median affinity: 9.699999809265137 pIC50
Reference (Journal): Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor.
Published in: Blood

Ligand: compound 8e [PMID: 24432909] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.699999809265137 pIC50
Reference (Journal): Design of potent and selective inhibitors to overcome clinical anaplastic lymphoma kinase mutations resistant to crizotinib.
Published in: J Med Chem

Ligand: compound 20 [PMID: 30998356] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.25 pKi
Reference (Journal): Design and Optimization Leading to an Orally Active TTK Protein Kinase Inhibitor with Robust Single Agent Efficacy.
Published in: J Med Chem

Ligand: belizatinib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.600000381469727 pKd
Reference (Journal): The discovery and optimization of a novel class of potent, selective, and orally bioavailable anaplastic lymphoma kinase (ALK) inhibitors with potential utility for the treatment of cancer.
Published in: J Med Chem
Target family: Type X RTKs: HGF (hepatocyte growth factor) receptor family (type: catalytic_receptor)
Target: MET proto-oncogene, receptor tyrosine kinase

Ligand: ensartinib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 9.130000114440918 pIC50
Reference (Journal): Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors.
Published in: Cancer Res
Target family: Type X RTKs: HGF (hepatocyte growth factor) receptor family (type: catalytic_receptor)
Target: macrophage stimulating 1 receptor

Ligand: MK-2461 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.149999618530273 pIC50
Reference (Journal): MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor.
Published in: Cancer Res
Target family: Type X RTKs: HGF (hepatocyte growth factor) receptor family (type: catalytic_receptor)
Target: macrophage stimulating 1 receptor

Ligand: merestinib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.920000076293945 pIC50
Reference (Journal): LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models.
Published in: Invest New Drugs